The role of ephrins and Eph receptors in cancer

被引：302

作者：

Surawska, H ^{[1
]}

Ma, PC ^{[1
]}

Salgia, R ^{[1
]}

机构：

[1] Univ Chicago, Ctr Med, Pritzker Sch Med, Sect Hematol Oncol,Dept Med, Chicago, IL 60637 USA

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2004年 / 15卷 / 06期

关键词：

Eph; Ephrin; cancer; lung cancer; targeted therapy; cytoskeleton;

D O I：

10.1016/j.cytogfr.2004.09.002

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Eph receptors are the largest receptor tyrosine kinase family of transmembrane proteins with an extracellular domain capable of recognizing signals from the cells' environment and influencing cell-cell interaction and cell migration. Ephrins are the ligands to Eph receptors and stimulate bi-directional signaling of the Eph/ephrin axis. Eph receptor and ephrin overexpression can result in tumorigenesis as related to tumor growth and survival and is associated with angiogenesis and metastasis in many types of human cancer. Recent data suggest that Eph/ephrin signaling could play an important role in the development of novel inhibition strategies and cancer treatments to potentially target this receptor tyrosine kinase and/or its ligand. A deeper understanding of the molecular basis for normal versus defective cell-cell interaction through the Eph/ephrin axis will enable the potential development of novel cancer treatments. This review emphasizes the biology of Eph/ephrin as well as the potential for novel targeted therapy through this pathway. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：419 / 433

页数：15

共 85 条

[1] The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration [J].

Adams, RH ;

Diella, F ;

Hennig, S ;

Helmbacher, F ;

Deutsch, U ;

Klein, R .

CELL, 2001, 104 (01) :57-69

[2]

Alves PMS, 2003, CANCER RES, V63, P8476

[3] Motility and invasion are differentially modulated by Rho family GTPases [J].

Banyard, J ;

Anand-Apte, B ;

Symons, M ;

Zetter, BR .

ONCOGENE, 2000, 19 (04) :580-591

[4] Expression of the receptor protein tyrosine kinase myk-1/htk in normal and malignant mammary epithelium [J].

Berclaz, G ;

Andres, AC ;

Albrecht, D ;

Dreher, E ;

Ziemiecki, A ;

Gusterson, BA ;

Crompton, MR .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 226 (03) :869-875

[5]

BOHME B, 1993, ONCOGENE, V8, P2857

[6] Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo [J].

Brantley, DM ;

Cheng, N ;

Thompson, EJ ;

Lin, Q ;

Brekken, RA ;

Thorpe, PE ;

Muraoka, RS ;

Cerretti, DP ;

Pozzi, A ;

Jackson, D ;

Lin, C ;

Chen, J .

ONCOGENE, 2002, 21 (46) :7011-7026

[7]

Carles-Kinch K, 2002, CANCER RES, V62, P2840

[8]

Carles-Kinch K, 2001, CLIN CANCER RES, V7, p3784S

[9] Phosphoinositide 3-kinase and the regulation of cell growth [J].

Carpenter, CL ;

Cantley, LC .

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1288 (01) :M11-M16

[10] EphrinA1-induced cytoskeletal re-organization requires FAK and p130cas [J].

Carter, N ;

Nakamoto, T ;

Hirai, H ;

Hunter, T .

NATURE CELL BIOLOGY, 2002, 4 (08) :565-573

← 1 2 3 4 5 6 7 8 9 →